

**"CLINCO - PATHOLOGICAL STUDY OF ACUTE RENAL COLIC AND
EVALUATION OF DICLOFENAC SODIUM AS AN ANALGESIC"**

THESIS

FOR

**MASTER OF SURGERY
(GENERAL SURGERY)**



**Bundelkhand University
JHANSI**

1991

MUKESH CHATURVEDI

C E R T I F I C A T E

This is to certify that the work
of Dr. Mukesh Chaturvedi on "CLINICO-PATHOLOGICAL
STUDY OF ACUTE RENAL COLIC AND EVALUATION OF
DICLOFENAC SODIUM AS AN ANALGESIC", which is being
presented by him for M.S. (General Surgery) examination
1991, has been carried out in the department of Surgery.

He has put in the necessary stay
in the department as per university regulations.

(R. P. Kala)

M.S.


Associate Professor & Head,
Department of Surgery,
M.L.B. Medical College, Jhansi.

Dated: 15.7.1991

C E R T I F I C A T E

This is certified that the work
embodied in this thesis entitled "CLINICO-PATHOLOGICAL
STUDY OF ACUTE RENAL COLIC AND EVALUATION OF DICLOFENAC
SODIUM AS AN ANALGESIC" has been carried out by
Dr. Mukesh Chaturvedi, under my guidance and supervision.

The method of work and results obtained
have been checked by me from time to time and are
genuine to the best of my knowledge.


(Dr. B. Pratap)
M.S.

Assistant Professor,
Department of Surgery
M.L.B. Medical College, Jhansi.

Dated: 15.7.1991

(GUIDE)

ACKNOWLEDGEMENT

At the outset, I acknowledge my heartfelt gratitude to my esteemed teacher Dr. Dinesh Pratap, M.S., Assistant Professor of the Department of General Surgery, M.L.B. Medical College, Jhansi, under whose expert and masterly guidance, I had an opportunity to work, even at his personal inconvenience. Without his generous advise, guidance, and unending efforts, this work could not have seen the light of the day.

I would like to acknowledge with a very special sense of gratitude, the co-operation and guidance extended to me by Dr. R.P.Kala, M.S., Associate Professor & Head, Department of General Surgery, M.L.B. Medical College, Jhansi.

I am highly thankful to Dr. B.L.Verma, Ph.D., Assistant Professor, Department of Social and Preventive Medicine, for his generous and valuable suggestions time to time.

I am equally thankful to Mr. D.P. saxena, P.S.R., J.B. Chemicals and Pharmaceuticals Ltd. The injection Diclofenac used in this study was kindly supplied by him.

Although, the burden of the work has to be borne by the worker himself, but such work can not be completed without the help and suggestions from good friends and well-wishers.

I am very much thankful to Dr. Sanjay Dubey, Dr. S.D.Saklani, Dr. K.K.Tanta and Dr. P.C.Purohit for their moral support, some valuable suggestions and meticulous criticism in compilation of this work together.

I am thankful to Mr. B.P.Tiwari and Mr. B.D.Sharma of M.R.D.section for their help in carrying out this study.


I have no words to express my gratitude to my parents, and my elder brother Shri R.C.Chaturvedi, without their affection understanding, sacrifice and blessing this study may well have not seen the light of the day at all.

Mukesh Chaturvedi
(Mukesh Chaturvedi)

C O N T E N T S

	<u>Page No.</u>
1. Introduction	1 - 9
2. Material & Method	36 - 43
3. Review of Literature	10 - 35
4. Observation	44 - 55
5. Discussion	56 - 69
6. Conclusions	70 - 73
7. Bibliography	74 - 85
8. Summary	attached separately

00000000
0000000
0000
00
0



INTRODUCTION

INTRODUCTION

According to Greek Mythology " the first men enjoyed complete happiness in golden age. They lived like a god, Free from worry and fatigue, old age did not afflict them, they rejoiced in continual festivity ". Their lot did not include immortality, but at least they died as though overcome by sweet slumber. But Pandora, opened her box and let loose all the afflictions of mankind.

Disease is as old as life on earth. With ever new ways, man always the experimenter, fought diseases from the day he was born on earth. For thousands of years he was a looser and only the strongest men survived.

Due to ignorance, the disease was considered to be caused by evil spirit and special prayers to various Gods were offered and superstitious reigns brutal and fake remedies were order of the day. Physicians jumped up and down on a sick child's stomach to drive disease out of him. They prescribed frog's eyes to cure human eye troubles. Diseases became "conqueror" and epidemics slaughtered countless millions. Magical symbols, Rx, which is representation of eye of Horus, the Egyptian God of healing and staff with two snakes, staff of Hermes (Mercury), mythical messenger of God's are being used by physician even today.

Though the malady of stone disease was known to physicians of earlier age than Hippocrates - no definitive cure except operative removal of stone was found to be satisfactory. The operation, itself was very dangerous and often fatal so that, even Hippocrates in his famous oath wanted physicians to refrain themselves from operation and leave it to be done by specialists in this art. " I will guard my life and my art, I will not use the knife on sufferers from stone, but I will give place to such as craftmen therein ".

Several words are used to describe the causative substance of this disease. Stone is the most common term, the word stone is derived from Greek word " Stear ", which means " Hard ".

'Concretions' - is a term derived from latin word " Concretus " concrete : a mass formed by coalescence of separate particles of matter in the body.

"Lithiasis" - means formation of concretions in the body. It is derived from Greek word ' Lithos' - means " stone" 'lithia' is white crystalline oxide of lithium.

'Calculus' is a latin word, which means pebble or stone in bladder, a concretions of mineral salts around organic material found in hollow organ or ducts. This terms really indicate one of theories of stone formation.

"Colic" - is a term derived from the latin word Colica (Kol-i-Kha), colic means acute paroxysmal abdominal pain.

Inspite of great progress made since Hippocratic era, the cause of stone formation is not clear. Many theories have been put forward to explain the cause and development of urologic calculi; Nucleation theory, stone matrix theory, inhibitors of crystallization theory but none have been able to answer all the questions. In all probability, stone disease may be due to interaction of multiple factors, many of which are yet unknown.

By 1950, investigators began to report some significant physiologic observations that were associated with production of urinary calculi. These included the importance of diet especially in association with uric acid bladder calculi (Gutman and Yu 1968).

Hypercalciuria was clearly defined as one factor contributing to the formation of calcium calculi and hypercalciures due to hyperparathyroidism was identified and separated from idiopathic hypercalciuria. Importance of Nucleation of stones in kidney was studied intensively by Randall (1937), who describe his Favours " Randall plaque", Urinary crystals and colloids were described, and the crystalloids and colloid composition of all

4

stones was determined. The effect of infection on stone formation was noted to be different from effects of excessive excretion of crystalloids in the absence of infection. Much ground work was laid for the worldwide resurgence of research into the etiology and prophylaxis of urolithiasis that followed world-war II.

Anderson² (1973) presents an interesting multifaceted theory of epidemiology of urinary calculi. He notes that the incidence of upper urinary tract calculi varies greatly with age, anatomic site and geographical distribution and that there are unexplained increases during different periods of history. He feels therefore that there are at least two separate epidemiological factors involved in the genesis of urinary calculi. The first of these may be considered intrinsic. Intrinsic factors are related to the inherited biochemical or anatomic make up of individuals. For example African Bantu natives and the related North American Negroes tend to have very few urinary calculi (Medlin⁶⁵ 1967, Pantowowitz et al,⁶⁶ 1973). A subcategory of this racial or ethnic factor includes any familial tendency towards generation of calculi. Familial inheritance of calcium stone disease has been reported and reviewed by Finlayson¹⁷ (1974) no true sex linked inheritance of urinary lithiasis has been

defined, but Boyce 1973 have reported that male relatives of patients with hypercalciuric stone disease were more often afflicted than female relatives. Intrinsic factors of urolithiasis, then included ethnic, racial or familial background and any inherited physico-logical or anatomic predisposition of urinary calculi.

Superimposed upon these apparent intrinsic factors are those that Anderson terms extrinsic. Another terms for these might be environmental factors. These include climate, water available for drinking, dietary patterns or populations and of household of people with urinary calculi, the presence or absence of trace elements in food stuffs and drinking water, differing age and sex distributions of types of calculi; and different occupations.

Recently Cee F.L. and Park J.H. (1988) observed that renal calculi are concretions consisting of crystals and matrix of organic matter. Crystals usually constitute the matrix predominant portion (90%) of the mass of most calculi but those occurring as a consequence of urinary tract infections have a higher proportion of matrix material. Renal calculi are to be distinguished from calcific deposits within renal parenchyma. Such deposits occurring at sites of previous inflammation or degenerative changes, are designated by the term "Nephro-calcinosis".

⁵²
Klahr, S et al (1986) reported that the type of calculous disease is modified by geographic factors, sex, race and probably diet. Males are affected more than females and the peak age of onset is between 30-50 years. Familial and hereditary predisposition to stone formation has long been known. Many of the inborn errors of metabolism, such as gout, cystinuria and primary hyperoxaluria, provide good example of hereditary disease, characterized by excessive production and excretion of stone formation substance.

Arruda, J.A.L. (1985) reported that there are many causes for the initiation and propagation of stones, the most important determinant is an increased urinary concentration of the stones' constituents, such that it exceeds their solubility in urine (Supersaturation). A low urine volume in some metabolically normal patient may also favour supersaturation. ⁵³
Kill P (1987), It can thus be appreciated that increased concentration of stone constituents, change in urinary pH, decreased urinary volume and the presence of bacteria influence the formation of calculi. However many calculi occurs in the absence of these factors, and conversely, patient with hypercalciuria, hyperoxaluria and hyperuricosuria often do not forms stones. It has, therefore postulated that change in urinary content

of mucoproteins that, form the organic matrix of urothils may be important or alternatively, that there is deficiency in inhibitors of crystal formation in urine. The list of such inhibitors is long including pyrophosphate, diphosphonate citrate and recently described glycoprotein called nephrocalcine, but no consistent deficiency of any of these substances has been demonstrated in stone formers (Klahr S et al, 1986).

Arruda J.A.L. (1983) reported that the renal colic arises from the kidney associated with the inflammation or obstruction at the level of the pelviureteric junction. Stones are of importance when they obstruct urinary flow or produce ulcerations and bleeding. They may be present without producing any symptoms or significant renal damage. In general small stones are most hazardous, as they may pass ureter. Producing pain referred to as colic as well as ureteral obstruction. Larger stones can not enter the ureters and are more likely to remain silent within renal pelvis. Commonly, these larger stone first manifest themselves by hematuria. Stone also predispose to superimposed infection, both by their obstructive nature and by the trauma they produce.

The pain of acute renal colic is usually severe and demands immediate and complete

relief. The established mode of therapy are (a) Narcotic analgesic often combined with spasmolytic agent, side effect and the risk of drug addiction indicate the need for an alternatives to narcotics (b) Non-narcotics analgesic-antispasmodic combinations. Baralgan is widely used example of the second group. It is a combination of dipyrone, which is an analgesic, a benzophenone components. Which is a smooth muscle relaxant and a diphenyl derivatives, which has a parasympatholytic actions.

⁵¹ Marsala F (1980) introduce recently, a third option has become available based on a better understanding of the physiological changes during ureteral obstruction and colic. This ureteric obstruction causes increased synthesis and release of prostaglandins.

⁴⁰ Lundström S. (1987) as a result renal pelvis pressure rises, causing renal colic. Prostaglandin inhibitors have been used to relieve the pain of renal colic. (Sikström L.P. and Carlson (1975).

¹⁵ ⁷⁸ Edmond C. K. U. (1974) reported that the diclofenac sodium (the sodium salt of O - (2, 6 dichlorophenyl)amino - phenylacetic acid) is a non steroidal antiinflammatory drug a potent prostaglandins synthetase inhibitor. It has been shown to relieve renal colic more effectively than other drugs. Diclofenac is normally advocated for use in painful and inflammatory rheumatic and certain non rheumatic conditions. It is

available in a number of administration forms, which can be given orally, intramuscular and rectally. Drugs 35 (1988) conveniently, dosage adjustment are not required in the elderly or in those patients with renal or hepatic impairment. The drug has a relatively short elimination half life, which limits the potential for drug accumulation.

63

Drugs 35 , 1988 in numerous clinical trials the efficacy of diclofenac is equivalent to that of many newer and established NSAIDs with which it has been compared. As an analgesic it has a fast onset and long duration of action. When administered intramuscularly, it is at least comparable to and frequently superior to many narcotic and spasmolytic combinations in renal and biliary colic.

Extensive clinical experience has been gained with diclofenac, clearly establishing its safety profile. It is well tolerated compared with other NSAIDs and rarely produce gastrointestinal ulceration or other serious side effects. Thus, diclofenac can be considered as one of the few NSAIDs of 'First choice' in the treatment of acute renal colic.

REVIEW OF LITERATURE

REVIEW OF LITERATURE
EXPERIMENTAL AND CLINICAL STUDIES
ON THE THERAPY OF STERIC OBSTRUCTION
IN THE URETHRA

REVIEW OF LITERATURE

Anthropologic history provides evidence that urinary calculi existed as long as 7000 years ago or perhaps more. The recognition of different varieties of urinary calculi also resulted in more varieties of medical treatment. During the last decade however, many major advances have greatly improved our understanding of the causes of stone disease. Karpukhin (1981). Although not all calculi can be cured, patients who develop one of the five major types of urinary calculi now have at least a 50 percent chance of cure or control with medical therapy alone. Surgery continues to be important as one aspect of treatment of urinary calculi, but it is now only one step in total therapeutic or the mentorium for patients with urinary lithiasis.

Urinary lithiasis is one of the most common disease of urinary tract. It occurs more frequently in men than women, a familial predisposition is often encountered. The history of stone disease implies that many factors might be involved in it's causation; heredity, environment, Age, Sex, Urinary infection, the presence of metabolic disease and dietary excess or deficiencies to review some of these factors, the epidemiological aspects of urinary calculi are helpful.

Epidemiological aspects of urolithiasis

Anderson² (1973) presented an interesting multifacted theory of epidemiology of urinary calculi. He felt that there were at least two separate epidemiological factors involved in the genesis of urinary calculi.

1. Intrinsic factors
2. Extrinsic factors

INTRINSIC FACTORS

1. Heridity - Numerous authors have noted that urinary calculi are relatively rare in the North American Indians, the Negroes of Africa and America, and the native born conversely the incidence of stone disease is known to be highest in some of the colder temperature of the world populated primarily by Eurasians and Caucasians. Various authors conclude that urolithiasis requires a polygenic defect (more than one gene involved). In addition, genetic predisposition to urinary lithiasis has partial penetrance, so that the severity of stone disease may differ from generation to generation even though individual has the gene defects necessary for urinary lithiasis.

Renal tubular acidosis is one hereditary disease that has been certainly associated with frequent episodes of urolithiasis. Cystinuria is a prime example of familial type of urinary lithiasis

that is definitely hereditary.

2. Age and Sex : The peak age incidence of urinary calculi occurs in the third to fifth decades. About 3 males are afflicted for every female. Burkland ⁶² Rosenberg 1965 have pointed out that the maximum incidence of urinary lithiasis appears to occurs in the 30 to 50 years age group.

⁴¹ Lonsdale (1968) observed the incidence of upper urinary tract calcification approximately equal in male and female at the time of autopsy.

Several authors have commented upon the apparently equal tendency towards urinary lithiasis in males and females during Childhood (Prince and ⁶² Scardine, 1960). This observation completed with reports that increased serum testosterone level resulted in increased endogenous oxalate production by liver, led ¹⁷ Finlayson (1974) to postulate that lower serum testosterone level may contribute to some of the protection that women (and children) enjoy against oxalate stone disease. Recently, Schremm and Carlson ⁷⁸ (1975) have demonstrated increased urinary citrate concentration in urine of females, and they postulate that this may aid in protecting female from calcium urolithiasis.

EXTRINSIC FACTORS

1. Geography :- There is noticeable increase in urinary calculi in mountainous or tropical areas. Boyce ⁸ et al

(1959) performed an extensive study of incidence of calculus disease in the united states. Other high incidence areas are the British isles, Scandinavia, Mediterranean countries, Northern India and China (Finlayson¹⁷ 1974).

2. Climatic and seasonal factors : It is difficult to find direct evidence for the influence of climate on occurrence of urinary lithiasis. Several authors, however have attempted to show a relationship between higher environmental temperature and increased seasonal incidence of urinary stone disease (Prince and Scardino, 1960; Elliott, 1975).

Elevated environmental temperature seems to be definitely related to increased risk of stone disease in population capable of forming stones. High temperature increases perspiration which may result in increased concentration of urine. This hyper-concentration could contribute to stone formation in many ways. For example if the individual has, as noted above, an inborn tendency towards formation of calculi, dehydration would result in decreased urine volume and increased urinary concentration of these molecules as well as excessive urinary acidity. These two changes promote crystalization of the respective molecules. In persons with a tendency to form calcium

calculi, urinary concentration of calcium oxalate and phosphate would increase, large crystal could form, possibly aggregating into stones. Patient with a tendency towards formation of uric acid or cystine calculi would have an additional risk because acid urine holds much less uric acid and/or cystine in solution. One admonition to stone formers as derived from these studies, then might be to "Keep Cool".

3. Water intake and urinary lithiasis : Two factors involved in the relationship between water intake and urolithiasis are the volume of water ingested as opposed to that lost by perspiration, and the mineral or trace elements content of water supply of the region. One of the prevailing assumption in the literature of urolithiasis is that increased water intake and increased urinary output decreases the incidence of urinary calculi in those patients who are predisposed to the disease. Finalyson¹⁷ (1974) demonstrated that increased urine flow causes a reduction in urine oxalate (concentration). However to be significantly effective a urine output of more than 3600 ml per day would be theoretically necessary.

4. Diet : There can be little doubt that dietary intake of various foods and fluids that result in increased urinary excretion of substances that produce stone has a significant effect on the incidence of urinary calculi. Peculiar dietary excesses may also occur. Such as use of large amount of

worcestershire sauce with its high oxalate content, vegetarian diet, or habitual excessive ingestion of milk products in the form of cream.

5. Occupation : Lonsdale indicated (1968b) that urinary calculi are much more likely to be found in individuals who have sedentary occupations. Blacklock (1959) reported that the incidence of urinary calculi was higher in administrative and sedentary personal of Royal Navy than in manual workers. Anderson (1973) emphasized that the relationship between diet and heredity is the major determinant for urolithiasis, but that occupation is also important. Occupation also tends to determine exposure to other factors such as high environmental temperature that may then increase tendency towards formation of urinary calculi.

Present Theoretical Basis of Etiology of urinary calculi

Modern concepts of urinary calculous disease may be separated conveniently into five major theories.

1. Supersaturation crystallization theory
2. The matrix nucleation theory.
3. The inhibitor absence theory.
4. Epitaxy
5. Combinations of above.

Supersaturation/Crystallization:- Uric acid and cystine calculi form whenever urine with a tendency to remain at

an acid pH becomes over saturated with uric acid or cystine. Magnesium ammonium phosphate calculi form whenever the product of concentration of these ions exceed the saturation product and when the urine remains alkaline for long periods of time.

Inhibitor lack : Blacklock⁷ (1969) have produced such a theory for calcium oxalate urinary lithiasis. Their study suggest that for calcium oxalate calculi an index of supersaturation versus inhibitor can be determined for an individual, and that stone formers show greater supersaturation and less inhibition of crystallization and stone formation.

Matrix initiation - Matrix is a derivatives of several of mucoproteins of urine. Matrix content of a given stone varies, but most solid urinary calculi have a matrix content of about 3 percent of weight (Boyce and King⁸ 1959) matrix may inhibit crystals growth interfere with crystal aggregation, and even enhance stone growth. At the present time the uromucoid of normal individuals is thought to be a beneficial inhibitor of crystallization and stone formation, whereas the matrix of stone formers represents uromucoid with some qualitative defect that alters it's ability to inhibit crystallization or even causes it to promote stone formation (Finlayson¹⁷ 1974).

Intranephronic and fixed nucleation :

Boyce and King⁸, 1954 & Finlayson¹⁷ 1974,

These workers state that the major process that ultima-

tely leads to stone formation is aggregation of small crystals formed previously in the kidney. Some investigators believe that the initial nucleation and growth of nuclei and crystals begin in the renal tissue (Intranephronic), while other believe that the process begins freely in renal tubular urine. Intranephronic calculusis is probably most important in calcium stone disease.

Extranephronic and free particle nucleation

Proponents of extranephronic theory of urinary stone formation believe that it all happens in urine. Hence one possibility of matrix theory of stone formation is the fact that uromucoid normally acts as an inhibitor. Patient with stone disease may lack some significant component of uromucoid or produce additional components that decrease its inhibiting action.

Epitaxy : If a crystal has a pattern or organization of ions that is regular and predictable, this structure is called a lattice. This surface lattice may resemble very closely that of second best different type of crystal. Depending upon closeness of resemblance, the second type of crystal may actually be able to grow upon the surface of the first. Epitaxy required oriented overgrowth of one crystal on the surface of the another.

Final Theory :

This final theory of urolithiasis is an attempt to comprise all the elements discussed pre-

viously

1. Renal function must be adequate for the excretion of excess amount of crystalizable substance.
2. Kidney must be able to adjust it's pH excretion to conform to that required to crystallize the substance.
3. Urine must have a complete or relative absence of a number of inhibitors of crystallization of the crystalizable components.
4. Crystal mass must reside in the urinary system for a time sufficient to allow growth or aggregation of crystal mass to a size large enough to obstruct the urinary passage through which it is proceeding. Hence stasis may have an important part in the genesis of urinary calculi.

RENAL/URETERIC COLIC

⁶ Bailey & Love's (1988) Renal pain is usually dull ache situated mainly in the costovertebral angle, but also in the upper and outer quadrant of the abdomen. Renal pain, when localized is usually felt in the back of the loin with its maximum intensity in the renal angle i.e. that angle between the outer border of erector spinae and the twelfth rib (Posterior renal pain).

It may also be felt over the front of the abdomen about one inch below the tip of the ninth costal cartilage (anterior renal pain). The pain is persistent and aching in character and is caused by stretching of the pelvis or capsule of the kidney. Sometimes

the patient feels pain in the opposite kidney which hypertrophies in order to compensate the impaired function of its fellow.

Renal or ureteric colic is due to violent contraction of the renal pelvis and ureter in order to expel a stone or blood clot. This is characterized by spasmodic pain that starts in the renal angle and radiates from the loin down to the groin, testis and inner side of the thigh i.e. along the distribution of the genitofemoral nerve, L₁ and L₂. As the obstructing agent comes down into bladder or falls back into the renal pelvis, the colicky pain passes off as suddenly as it came. (K. Das 1990). ²⁹

The pain of acute renal colic is usually severe and demands immediate and complete relief. The established mode of therapy are

- a. Narcotic analgesic often combined with spasmolytic agent. However side effects and the risk of drug addiction indicated the need for an alternatives to narcotics.
- b. Non narcotics - analgesic- antispasmodic combination, Baralgan is widely used example of the second group. It is a combination of dipyrone, which is an analgesic a benzophenone component, which is a smooth muscle relaxant and a diphenyl derivatives, which has as a parasympatholytic action.

Recently, a third option has become available based on a better understanding of the physiolo-

sical changes during ureteral obstruction and colic.
³³
(Kill.F., 1987).

This ureteric obstruction causes increased synthesis and release of prostaglandins. As a result renal pelvic pressure rises, causing renal colic. Prostaglandin inhibitor have been used to relieve the pain of renal colic. (Seharm and Carlson ⁷⁸ 1975).

Finally since prostaglandin acts as a intermediaries in pain transmission, impairment of prostaglandin synthesis may have a direct effect on pain perception. This striking effect may be explained by the reduction of the rise in intrapelvic pressure mediated by the release of prostaglandin in the renal medulla during ureteric obstruction. Prostaglandins inhibitor have been used to relieve the pain of renal colic.

Out of many NSAIDs Diclofenac sodium, the sodium salt of o-(2,6-Diclophenylamine) - Phenyl acetic acid is a non steroidial antiinflammatory drug a potent prostaglandins synthetase inhibitor has been reported to relieve renal colic more effectively than the previously used drugs. Drugs ⁶³ 35 (1988).

PHARMACODYNAMIC PROPERTIES

Diclofenac is NSAII drugs with analgesic and antipyretic activity and is common with other aspirin like antiinflammatory drugs, it is potent inhibitor of

prostaglandin (PG) synthesis. It is phenylacetic acid derivative, (Sallmann, 1986) and it is extensively metabolised, but none of its metabolites possess significant pharmacological activity compared with other drugs which inhibit the prostaglandin synthesis (Maier ⁴⁸ et al 1979; Menasse et al, 1978).

Anti-inflammatory activity : Diclofenac is active in suppressing inflammation and oedema induced by carrageenan, (Krupp et al 1975) mustard or croton oil. In addition, the drug also suppresses cotton pellet granuloma formation (Deriette de meneses, 1985) and vascular permeability induced by human plaque in rats. Diclofenac also effective in reducing primary and secondary inflammation in adjuvant arthritis. In these tests the potency (Weight for weight) of diclofenac was similar to that of indomethacin, greater than that aspirin, ibuprofen, naproxen and phenylbutazone and less than that of piroxicam.

The anti inflammatory activity of diclofenac is not caused by stimulation of the hypothalamic-pituitary adrenocortical axis, as the effect is maintained in adrenalectomised rats (Krupp et al 1975).

Analgesic activity - Diclofenac is an effective analgesic in rats and mice, inwhich it inhibits writhing induced by ethaerynic acid (Menasse ⁵⁴ et al, 1978) acetic acid (Menasse ⁵⁴ et al; 1978; Noguchi et al, 1984 etc.) Phenylbenzoquinone ⁵⁷ (Menasse et al 1978) and yeast. It is also effective in

raising threshold of adjuvant induced arthritic pain (Noguchi et al, 1984). The potency of diclofenac in these tests was similar to that of indomethacin and piroxicam but greater than that of aspirin, ibuprofen, naproxen and phenyl butazone.

In a placebo-controlled double blind study (Stacher et al, 1986), the analgesic activity of single oral doses of diclofenac 75 mg and 150 mg was compared with codeine 60 mg in relieving experimental pain induced by the electrical and thermal stimulation of skin in 48 healthy human subjects. Pain threshold values increased with all active treatment compared with placebo, diclofenac 150 mg was more potent than codeine 60 mg. Which was in turn more potent than diclofenac 75 mg. Codeine produced more side effects than placebo and diclofenac, while diclofenac and placebo were similarly well tolerated.

Sacerdote et al (1985) found that diclofenac 100 mg/kg administered to rats decreased pituitary B endorphine and increased hypothalamic concentration of the peptide. The same group of workers studied the effect of diclofenac 150 mg/day or placebo for 2 days in 8 patients with extracranial shunt (Martini et al, 1984). Plasma Endorphin concentration were increased nearly four fold on diclofenac ($P < 0.025$), while placebo had no effect. There were no changes in Endorphin

phin and either serotonin or catecholamine metabolites in cerebrospinal fluids. The authors suggested that B-endorphins may contribute to the potent analgesic activity of diclofenac.

Antipyretic activity :- In rats with yeast induced fever the dose of diclofenac required to reduce body temperature by 1.5°C was less than with indomethacin, ibuprofen, Phenylbutazone, naproxen and aspirin (Menasse *et al*, 1978).

Gastrointestinal effects:- Controlled studies in healthy subjects measuring faecal blood loss or using endoscopic examination show that diclofenac sodium causes less gastrointestinal damage than aspirin, feprazon or naproxen, but more than fenofenac.

⁵⁹ *Canes et al* (1979) found that diclofenac 100 mg/day caused significantly ($p < 0.02$) less gastritis and haemorrhagic and erosive lesions of the gastroduodenal mucosa than naproxen 500 mg/day in 14 subjects. *Lethola and Sipponen* (1977) compared the gastric damage induced by diclofenac 75 mg/day and naproxen 500 mg/day in 6 subjects. Erosions tended to occur more frequently with naproxen, but too few subjects were enrolled for valid statistical analysis.

Several studies have measured faecal blood loss using the ^{51}Cr -labelled erythrocyte technique. ⁸¹ *Uthgenannt* (1981) reported faecal blood loss over a 3 weeks period totalling 32 ml to 174 ml in 8 subjects given aspirin 3 mg/day, 23 to 167 ml with naproxen 750mg/day and 19 to 39 ml with diclofenac 150 mg/day. In a one week

crossover study in 6 subjects (Uthgenannt, 1977), mean daily blood loss with naproxen 750 mg/day (4.9 ml) was greater than with diclofenac 150 mg/day (2.0 ml) or feprazone 800 mg/day (3.7 ml). In another one week crossover study in 6 subjects (Uthgenannt and Letzel, 1981) the mean increase in daily blood loss with diclofenac 150 mg/day (0.91 ml) was greater than with fenofenac 1200 mg/day (0.74 ml) and 900 mg/day (0.56 ml).

To assess gastric irritation (Brendl et al, 1983; Bruhn et al 1982) by single oral dose of ¹⁰ ibuprofen 150 mg, diclofenac 50 mg and piroxicam 20 mg produced similar effect, indomethacin 50 mg and aspirin 500 mg caused significantly more irritation.

Effect on arachidonic acid metabolism

Diclofenac is a potent inhibitor of cyclooxygenase (Prostaglandin synthetase) in vitro, as measured by the marked reduction in synthesis of prostaglandin Prostaglandin and thromboxane products. At high concentrations in vitro diclofenac did not inhibit phospholipase A_2 , which controls arachidonic acid formation from phospholipids and had negligible effects on the ⁵⁹ 5 and 15 lipoxygenase enzyme (Ku et al, 1985, 86). However these authors showed that formation from phospholipids from the lipoxygenase pathway (Leucotrienes and 5 hydroxyeicosatetraenoic acid) is reduced by high concentration of

diclofenac in vitro and ex vivo in rates and human leucocytes. This seems to be caused by the decreased availability of intracellular arachidonic acid, ~~which~~, which result from enhanced reincorporation of this substrate into the tryglyceride pool. This effect on lipoxygenase in inflammatory products may contribute to the anti-inflammatory effect of diclofenac in vivo, but the formation of cyclo-oxygenase is probably the primary site of action.

In vivo, diclofenac decreased urinary PGF₂ and PGE₂ in rabbit renal medulla (Oliw et al, 1978) and PGE₂, 6 keto -PGF₁ alpha and PGI₂ in the gastric mucosa of human.

⁷⁴ Seppala et al (1985) found that diclofenac 200 mg administered orally in divided doses over 1 day significantly (P/ 0.05) reduced PGE₂ and thromboxane B₂ (by 50 - 60%) and tended to reduce 6 Keto PGI₁ alpha (by 30%) in the synovial fluids of patients with rheumatoid arthritis. The effects of diclofenac were more pronounced than approximately equivalent therapeutic dosages of the other NSAIDs tested (aspirin, carprofen, indomethacin). Naproxen, proquazone and tolfenamic acid). The authors suggested that these agents which produced the best relief of acute pain in rheumatoid arthritis were the most potent inhibitors of prostaglandins in synovial fluid.

⁶⁸
 Raimann and Frolich (1981) found that 24 hours urinary excretion of PGF₂ was decreased by about 50% when diclofenac 150 mg daily was administered to 5 healthy women for 7-10 days. This might effect prostaglandin dependent renal function such as natriuresis and lithuresis.

Effect on Renal function : A single oral dose of diclofenac 50 mg did not have any significant influence on uric acid excretion in 5 rheumatic patients with normal renal function (Tiitinen ⁷⁹ et al 1983).

⁸⁵
 In a non-blind study Vandenburch et al (1984) 62 elderly patients with osteoarthritis received diclofenac 75 mg/day or Sulindac 400 mg/day for 12 weeks. Mean blood urea increased (P<0.05) from 7.63 to 9.17 mmol/L on diclofenac but was unchanged on sulindac. Clinically significant increases in blood urea nitrogen have been rarely reported during treatment with diclofenac.

⁴²
 Laurent et al (1987) treated 29 patients with membranoproliferative or IgA glomerulonephritis with diclofenac 100 mg/day or placebo in a randomised double blind study. Diclofenac produced a significantly greater median decrease in proteinuria after 2 months treatment compared with placebo (-70% - 6%) P<0.01). Thus, while diclofenac exerted a short term antiproteinuria effect. It remains to determine whether it has any therapeutic value in affecting the final outcome of glomerulonephritis.

Other effects in brief

a) Carbohydrate metabolism - Diclofenac 150 mg/day had no adverse effect on blood glucose concentration or 24 hours urinary glucose excretion in 13 maturity onset diabetics treated with diet alone, or in another 14 maturity onset diabetics well controlled with diet and tolbutamide 500 -2000 mg/day (Schlumpf 1978). Oral administration of diclofenac 50 mg to 6 healthy subjects did not affect blood glucose concentration, plasma free fatty acids concentration increased about 0.5 to 0.9 mmol/L ($p < 0.05$).

b) Platelet aggregation - In common with other NSAIDs, diclofenac is a potent inhibitor of the secondary phase of human platelet aggregation in vitro (John and Gagnon 1971). At low concentration the drug inhibits secondary aggregation by ADP and adrenaline, and aggregation with collagen.

c) Hormones :- Administration of SR diclofenac 100 mg/day for 22 days to 10 rheumatic patients had no significant effect on plasma kallikrein concentration. However, mean urinary excretion of kallikrein was reduced to about one half of the control value after 15 days, which was not statistically significant and recovered after another week (Gross ²¹ et al, 1984). Mean plasma renin activity and aldosterone were reduced to 61.6% and 68% of control value respectively, after administration of diclofenac 150 mg/day to 20 healthy subjects for 3 days.

Leucocyte function : While NSAIDs are thought to exert their effects mainly by inhibiting prostaglandin synthesis, It has also been postulated that they inhibit a number of leucocyte responses such as lysosomal enzyme release and superoxide production (Priman et al 1986), which appear to play a role in the pathogenesis of rheumatic disease and in the degradation of connective tissue and joints.

Pharmacokinetic properties (Brief):- Diclofenac is rapidly and efficiently absorbed after conventional oral, rectal or intramuscular administration. After intramuscular administration peak plasma concentration are attained after 10-30 minutes. With the enteric coated formulation peak concentrations are reached after 1.5 to 2.5 hours and this is delayed by food to 2.5 to 12 hours. After a single 50 mg dose of these formulations, mean peak plasma concentration of unchanged diclofenac are 0.7 to 1.5 mg/L. No clear peak concentration are found after a single 100 mg dose of sustained release diclofenac, although mean concentration was about 0.1 mg/L at 2 hours. Peak plasma concentrations and area under the plasma concentration time curve are linearly related to dose over the range of 25 to 150 mg regardless of administration routes, and no accumulation occurs after repeated doses. (John ²⁸ 1979; Kendall et al ³¹ 1979; Geiger et al, ²⁰ 1975, Willis et al, ⁸⁶ 1979).

Like other NSAIDs, diclofenac is highly (7, 99.5%) protein bound. The mean total volume of distribution is .12 to .17 L/Kg and that of central compartment is .04 L/Kg. The drug efficiently penetrates inflamed synovial fluid where high concentrations are maintained compared with plasma concentrations. Diclofenac and its metabolites cross the placenta in animals, and small amounts may be found in the breast milk of women (Riess et al, 1978; Chamouard et al, 1985; Manger and Sule ⁶⁹ 1979; Aylward et al, 1980; Benson et al 1985; Liaw ⁴⁴ et al, 1985; etc.).

Diclofenac undergoes significant first pass metabolism and only 60% of the drug reaches systemic circulation unchanged following oral administration. It is eliminated principally by hepatic metabolism and subsequent urinary and biliary excretion of glucuronide and sulphate conjugates of the metabolites. The principle metabolite in human is 4-hydroxydiclofenac, which possess negligible anti-inflammatory activity compared with the parent drug; the amount excreted in urine accounts for 20-30% of the dose and that in bile for 10-20%. The mean elimination half life after a radio-labelled dose is about 30 hours for the tracer.

Age and renal or hepatic impairment do not appear to have any significant effect on plasma

concentration of unchanged diclofenac, although metabolite concentrations may be increased by severe renal impairment.

Stierlin ⁷⁶ et al, 1979; Willis ⁸⁶ et al 1979; Kendall ³¹ et al, 1979; Menasse ⁵⁴ et al, 1978; etc.)

THERAPEUTIC USE IN RENAL COLIC : Prostaglandin are implicated in the aetiology of renal and biliary colic, and it was hypothesised that an effective treatment might be provided with prostaglandin synthetase inhibitors. Among them intramuscular diclofenac has been found to provide rapid and effective relief of pain (Kanter ³⁰ 1986; Kral ⁵⁷ 1985).

Preliminary non-comparative studies indicated that single intramuscular dose of diclofenac 25 to 75 mg were effective in renal (Naveh 1982) and biliary colic (Lundstrom ⁴⁰ et al, 1983) In subsequent comparative studies intramuscular diclofenac 50 mg and, more often, 75 mg employed. Diclofenac was clinically effective compared with placebo. Onset of analgesia occurred within 15 minutes and was maximum with in 30 minutes. No decline in analgesia occurred until 4 hours after injection. In responders complete analgesia occurred in most patients treated with diclofenac, while few of those on placebo also had a complete response.

Diclofenac 50 to 75 mg was superior in efficacy both statistically and clinically, to many narcotics and spasmolytic combinations, although similar efficacy was found to indomethacin (Comeri et al 1984) and pentazocine (30 mg Quitez et al 1984). In a non blind study (Sami Khalifa, 1986) ⁷² Intramuscular diclofenac 50 mg and as intravenous combination of pethidine 50 to 100 mg plus hyoscine butylbromide 20mg were effective in 90% and 97% of patients, respectively.

Side effects : Diclofenac rarely produced any side effects, but minor, although statistically significant, reduction in blood pressure and heart rate occurred in some studies (Greassi ²² et al, 1986; Lundstram ⁴⁰ et al, 1982, 1985, 1987). However, diclofenac rarely produced the frequent limiting CNS effects (Nausea, vomiting, dizziness, sweating, euphoria) associated with narcotic analgesics which were often cited as a limiting factor in narcotic use even when they demonstrated similar efficacy to diclofenac (Quitez et al, 1984; Sami Khalifa and Sharkewi ⁷² 1986).

Following is the summary of results of randomised double blind clinical trials comparing single intramuscular doses of diclofenac with placebo, narcotic, analgesics and spasmolytic agent in patient with renal colic.

Reference	Dose (No. of patients)	Response rate (%)
Lundstam et al (1980) ⁴⁰	Diclofenac 75 mg (9) Placebo (10)	100 30
Lundstam et al (1982) ⁴⁰	Diclofenac 50 mg (34) Spasmofen (32)	91 63
Comeri et al (1984) ¹²	Diclofenac 75 mg (27) Indomethacin 50mg(24) Noramidopyrine 1 g+ Pitofenone .4 mg + Fenpiverine .04 mg(24)	74 79 42
Neveh et al (1984) ⁵⁶	Diclofenac 75mg (19) Papaverine 80mg (13)	84 24
Quitez et al (1984) ⁶⁴	Diclofenac 75 mg (24) Byescine butylbromide 20mg (23) Pentazocine 30 mg (14)	78 26 79
Hetherington & Philip (1986) ²⁶	Diclofenac 75 mg (24) Pethidine (28)	95 65

MEASUREMENT OF PAIN

Huskission (1974) of the various methods for measuring pain the visual analogue scale seems to be the most sensitive. For assessing response to treatment a pain relief scale has advantages over a pain scale. Pain can not be said to have been relieved unless pain or pain relief has been directly measured.

Scale A (Simple descriptive pain scale): Keele (1948) described a four points scale, grading pain as slight, moderate, severe and agonising. Agonising pain is rare, and this grade has been dropped by most subsequent users of the scale. The term "mild" is often used instead of "slight". A patient with slight pain has only one possible grade of improvement complete relief, which is seldom achieved by simple analgesics in chronic pain. (So in this study we used only moderate and severe pain) because in this study any patient has not been found of mild pain.

Hewer et al (1949) used this scale to measure the effects of narcotics analgesics, and it remain a useful standard method with the advantage of simplicity. The disadvantage of the method is its lack of sensitivity (Huskission 1970).

The external distress manifested by the patient was graded by the assessor on a scale 1 to 4, 1

represented a patient who was absolutely comfortable while 4 meant a patient who appeared severely distressed.

Scale B (visual analogue scale): some of the problem of the simple descriptive pain scale can be overcome by using either a visual analogue or the graphic rating method. Clarke and Spear (1964) used a visual analogue scale to measure well-being, and concluded that it was both reliable and sensitive, though it is difficult to establish reliability in repeated measurements of subjective states, that is no reason to expect that pain would remain constant even from one minute to the next.

Freyed (1923) patients find simple descriptive pain scale easier than visual analogue pain scale. Berry and Huskisson²³ (1972) described that all patient were able to complete a simple descriptive pain scale, 7% were unable to complete visual analogue scale on the first occasion after a single adequate explanation of the method, and 3% were unable to complete graphic rating scale. Patients may require painstaking explanation from a trained assistant, especially on the first few occasions.

This scale has not been included in our study because of the fact that most of the patients coming to our M.L.B. Medical College Hospital, Jhansi belong to rural background and Bundelkhand being a backward area of the state.

scale C (Pain relief Scale):- charted relief of pain
An analogue scale was used in which the patient
expressed relief of pain in terms of "Annes-in-rupee".
Thus percentage of relief of pain was charted on
scale as a fraction e.g. $2/16$, $4/16$, $6/16$ etc.
(SHAH et al 1986)

Criteria of relief :-


Result were assessed as per the
following criteria.

1. Onset of action :- Time taken to achieve 25%
relief i.e. $4/16$ on scale C. The moment of starting
the injection of the drug is considered as
zerotime.

2. Adequate

Complete relief :- was said to have occurred only
if an when the patient reached a score of 1 or 2
on scale A (i.e. Nil/Mild discomfort) and had
relief of atleast $14/16$ on scale C (i.e. 90%
relief with only minimal residual soreness and
had no colic at all.

3. Partial relief:- Mild persistant colic or signi-
ficant residual soreness at 30 minutes (i.e.
score 3 on scale A and relief of not more than
 $12/16$ on scale C was rated as partial relief
only.



MATERIAL AND METHOD

1. *Material*
2. *Method*

MATERIAL AND METHOD

The present study was done from April, 1990 to April, 1991 in the department of Surgery, M.L.B. Medical College Hospital, Jhansi (U.P.). It comprised three hundred twenty five (325) patients of all age groups and both sexes, who had clinically proved renal/ureteric colic. All those cases who could not be completely assessed have been excluded from the study.

The present study was conducted with the following objectives:

1. Clinico-pathological study of renal colic patients based on clinical finding and urine analysis etc.
2. To evaluate the diclofenac sodium as a analgesic in acute renal colic.

METHOD

1. HISTORY : A detailed history was taken regarding following points :
 - a. Age : Age of the patient at the time of admission was noted and patient were kept in six age groups :- 6-14, 15-25, 26-35, 36-45 and 46-55.
 - b. Sex : Patients were kept in two groups i.e. male and female.

c. Religion: Patient were kept in two groups according to their religion Hindu and non Hindu.

d. Occupation: Exact occupation of each patient was noted and patients were kept in three categories; highly active moderately active and sedentary. Highly active group included Farmers and Laboures etc. Moderately active group included students, house wifes, service persons and children, sedentary group included executive class persons and elderly persons.

e. Socio-economic status : Socio economic status of each patient was decided as per capita income of his family. Per capita income was calculated by dividing total Family income with number of family members. There are five classes based on per capita income per month. Class I 7 Rs. 600/- , Class II Rs. 590/- to Rs. 300/-, Class III Rs. 299/- to Rs. 140/- Class IV Rs. 139/- to Rs. 60/- and Class V 7 Rs. 60/-

We grouped the patients in three categories i.e. High socio-economic status (Class I) Middle socio-economic status (Class II + Class III) and low socio-economic status Class (IV & V) category.

f. Marital status :- Patient were kept in two groups i.e. married and unmarried.

g. Complaints :- Following chief complaints have been noted along with their duration. Patient were kept in Four groups according to their duration of symptoms; ≤ 1 months, ≤ 2 months, ≤ 3 months and > 3 months.

A. Pain :- Following points were asked in relation to pain :-

i. Duration : exact duration of pain was noted.

ii. Time of occurrence: Exact time of pain was noted.

iii. Nature : Wheather pain was constant or intermittent in nature with periods of remission, was noted.

iv. Frequency: numbers of occurrence of same type of pain was noted.

v. Radiation: Radiation of pain if any, to other point was noted, and any referred pain was also noted.

vi. Character: Character of pain, it being

burning, penetrating, cutting or dullach was also noted.

vii. Relationship of pain with meal, posture and movement was also noted.

B. Vomiting/Nausea :- Those cases in which nausea/vomiting associated with pain its number, amount of vomitus, colour of vomitus and effect of vomiting over pain was noted. (increased or decreased).

C. Burns during micturition :- Following points were noted in relation to burning during micturition.

i. Duration : Duration of burning during micturition and whether it preceeded or followed the pain was asked for and noted.

ii. Severity : Severity of burning during micturition and its occurrence during exact point of micturition was noted.

D. Retention of urine :- If there was retention/inhibition of urine due to pain or burning during micturition, was also noted.

E. Change in colour of urine :- Following points, were noted under this headings :-

i) Colour of urine Exact colour of urine passed, was noted: bright red or smoky (Haematuria), opaque (Chyluria) or hazy (Pyuria).

ii) Time of occurrence : Maximum change, in the colour of urine was noted during which part of micturition.

categories; purely vegetarians included patients who only eat vegetarian diet like Dal, green leafy, tomatoes, milk and milk products; predominantly vegetarian included those patients who occasionally eat non vegetarian diet like meat, fish, chicken etc. Purely non vegetarians included those patient who only eat fish, meat etc. Predominantly non-vegetarians, included those patient, who predominantly eat meat, fish etc.

2. Physical Examinations :- Stress was given specially to the examination of abdomen, with special reference to any lump in the lumber region, fullness and tenderness in renal angle and examination of external genitalia.
3. Investigations :- Following investigations were done:
TLC, DLC, Hb, Blood sugar and Blood urea were done.
- b. Urine :- Albumin, sugar, microscopic examination for casts, crystals, R.B.C, puscells and epithelial cells was done.
- c. Radio logical
 1. Plain X-ray KUB was done in all cases to see the site and size of stone or if there is no radio opaque shadow in clinically diagnosed cases.

Patient were kept in four groups on the basis of site of stone; patient with stone above the ureter (pelvis and kidney), patient with stones in upper 1/3 of ureter (up to lower border of L₃ vertebra), patient with stone in middle 1/3 of ureter (from lower border of L₃ vertebra to lower border of sacroiliac joint) and patient with stones in lower 1/3 of ureter (from lower border of sacroiliac joint) to uretero-vesical junction.

ii. I.V.U: Intravenous urography was done to see the functions of kidney and to see radiolucent stones.

General Examinations:

B.P., Pulse rate and respiratory rate were noted at the time of admission.

Treatment and progress:

Treatment plan of these patients was as follows:-

- i. All patient were admitted to emergency or surgery ward with acute renal/ureteric colic, included in study group.
- ii. The diagnosis was confirmed by the clinical signs and symptoms.
- iii. Patient who fulfilled the clinical criteria of acute renal/ureteric colic were allocated to treatment with intramuscular injection of 1 ampoule of diclofenac sodium (Dicloren 3 ml, 75 mg).

iv. Patient with a history of allergy, asthma, bleeding disorder, peptic ulceration, women in pregnancy and those who had been given analgesics 6 hours before admission were excluded.

Methodology

After preliminary examination and recording of B.P. Pulse rate, the pain was assessed by scale A (Keele, 1948), as a mild, moderate or severe. The diclofenac injection was then given intramuscularly (deep gluteal region) over a period of not less than one minute. On completion of the injection, the analgesic effects of injection diclofenac was assessed after 15 and 30 minutes after the injection and evaluated the patient relief in pain as per scale C (R.S. Shah, 1986), and it was noted as " no effect ", " partial relief " or " complete relief ". At the end of 30 minutes of injection B.P. (Systolic/Diastolic), and pulse was again recorded. The patient was also asked if he/she experienced drowsiness, nausea, vomiting, dry mouth or any other side effects and they were similarly recorded.

O B S E R V A T I O N S

O B S E R V A T I O N S

These observations were made on patients (325) who were diagnosed as suffering from Acute renal/ureteric colic and admitted in hospital irrespective of age, sex, religion, socio economic status, occupation etc. coming to M.L.B. Medical College, Hospital, Jhansi between April, 1990 to April, 1991.

TABLE NO. 1

Cases of Acute Renal/ureteric colic related to total hospital admissions.

Total hospital admissions	Cases of ureteric colic	Percentage in relation to hospital admissions
26070	720	2.77%

Above table shows:-

1. 2.77% of hospital admissions are of acute renal/ureteric colic cases.

TABLE NO. 2

Incidence of acute renal/ureteric colic by sex.

Total number of cases	Males	Percentage of males	Female	Percentage of females
325	243	75%	82	25%

Above table shows:-

1. Male :Female ratio of acute renal/ureteric colic is 3:1.

TABLE NO. 3

Incidence of Acute renal/ureteric colic by age.

Age groups	No. of patients	Male Percentage of males	Female Percentage of females	Total
6 - 14	6	5	1.54	1
15-25	118	86	25.70	32
26-35	148	104	32	44
36-45	35	30	9.23	5
46-55	18	18	5.54	-
Total	325	243	74.71	82
				25.23 app. 100.00

Above table shows:-

1. Maximum incidence of ureteric colic is in the age group 15-35 years (81.08%).
2. No cases of ureteric colic found below 5 years and above 55 years.
3. Minimum incidence of ureteric colic is in age of 6 - 14 years.

TABLE NO. 4

Incidence of Acute renal/ureteric colic by religion.

Religion	Number of patients	Percentage of patients
Hindu	286	88%
Muslim	25	7.07%
Others	16	4.92%

Above table shows:-

1. Maximum incidence of ureteric colic among Hindus (88%).

TABLE NO. 5

Incidence of Acute renal/urteric colic by occupation.

Type of occupation	Number of patient	Percentage of patients
Highly active	173	53.26%
Moderately active	128	39.36%
Sedentary	24	7.38%

Above table shows:-

1. Incidence of ureteric colic is highest (53.26%) in highly active patients i.e. Labourers, Farmers etc.
2. Incidence of ureteric colic is lowest in sedentary patients i.e. elderly people and executive class persons.

TABLE NO. 6

Incidence of acute renal/urteric colic in relation to socio economic status.

Socio economic status	No. of patients	Percentage of patients
Low	32	9.84%
Middle	196	60.28%
High	97	29.84%

Above table shows:-

1. Incidence of ureteric colic is highest in middle class patient (60.28%).
2. Incidence of ureteric colic is lowest in low class patient (9.84%).

TABLE NO. 7

Incidence of Acute renal/ureteric colic in relation to dietary habits.

Dietary habit	Number of cases	Percentage of patients
Pure vegetarian	88	27.04%
Pre-dominantly vegetarian	202	62.12%
Pure non-vegetarian	-	-
Pre-dominantly non-vegetarian	35	10.76%

Above table shows:-

1. Incidence of ureteric colic is maximum in pre-dominantly vegetarian (62.12%).
2. No patient in our series was pure- non-vegetarian.

TABLE NO. 8

Incidence of Acute renal /ureteric colic in relation to alcohol consumption.

Type of patient	Number of patients	Percentage of patients
Alcoholic	68	20.92%
Non-alcoholic	257	79.08%

Above table shows:-

1. Ureteric colic are less common in persons consuming alcohol (20.92%).
2. Ureteric colic are more common in person not consuming alcohol (79.08%).

TABLE NO. 9

Incidence of various symptoms at the time of admission

Symptoms	Number of patients	Percentage of patients
Pain	325	100%
Haematuria	71	21.84%
Burning micturition	161	49.56%
Retention of urine	2	.60%
Lump	1	.28%

Above table shows:-

1. Pain was the commonest symptom at the time of admission. It was present in all cases (100%).

2. Burning micturition was next common complaints (49.56%).

TABLE NO. 10

Microscopical examination of urine in clinically diagnosed acute renal/ureteric colic cases.

Microscopical examination of urine	Number of patients	Percentage of patients
Pus cells	71	21.85%
R.B.C.	132	40.92%
Epithelial cells	62	19.22%
Crystals/cast	32	9.92%
Within normal limits	146	45.25%

Above table shows :-

1. Incidence of abnormal number RBCs is maximum 40.92% in urine.

2. Incidence of crystals is lowest in all cases.

TABLE NO. 11

Incidence of radio-opaque shadow (stone).

Number of patient clinically diagnosed as acute renal/ureteric colic	Number of patients in whom radio-opaque shadow present (suggestive of stone)		Number of patients in whom no radio-opaque shadow seen	
	No.	%	No.	%
325	130	40%	195	60.45%

Above table shows:-

1. No radio-opaque shadow is present in 60.45% of cases.
2. Incidence of radio-opaque shadow is present in 40% cases.

TABLE NO. 12

Incidence of acute renal/ureteric stone in relation to site.

Site of stone	Number of patients	Percentage of patients
Kidney + P.U.J.	55	42.30%
Upper one third of ureter	27	20.77%
Middle one third of ureter	16	12.31%
Lower one third of ureter	32	24.62%

Above table shows:-

1. Incidence of ureteric stone is maximum 75(57.70%).
2. Incidence of ureteric stone is minimum in middle one third of ureter 16(12.31%).

TABLE NO. 13

Incidence of stone in relation to side.

Number of patients	Side	Number of patients	Percentage of patients
150	Right	94	72.31%
	Left	36	27.70%

Above table shows:-

1. Incidence of stone is more on right side 94(72.31%).
2. Ratio of right : left is 3:1 approximately.

TABLE NO. 14

Incidence of positive intravenous pyelography.

Number of patient	Number of patients in whom I.V.P.done	Patient with positive findings due to stone		Patient with negative I.V.P.	
		No.	Percen-	No.	Percen-
325	92	82	89.13%	10	10.86%

Above table shows:-

1. No positive finding is present in 10(10.86%) cases.

TABLE NO. 15

Division of patient according to degree of pain.

Number of patient	Mild Pain		Severe pain		
	No. of cases	Percentage	No. of cases	Percentage	
325	0	152	46.76%	173	53.24%

Above table shows:-

1. Incidence of severe pain is maximum 53.24%.
2. Incidence of mild pain is not present in our series of study.

TABLE NO. 16

Effect of Diclofenac injection on patients having moderate pain after 15 minutes and 30 minutes.

Number of patient	Nature of effect	Number of patient response after 15 minutes	Per cent of response after 15 minutes	Number of patient response after 30 minutes	Per centage.
152	Complete relief	62	40.79%	131	86.22%
	Partial relief	90.	59.21%	21	13.88%

Table shows:-

1. Incidence of partial relief is maximum after 15 minutes 59.21%.
2. Incidence of complete relief is maximum after 30 minutes of injection 86.22%.
3. Incidence of no effect (response) after 15 and 30 minutes is not present in our series of study.

TABLE NO. 17

Effect of Diclofenac injection on patients having severe pain after 15 and 30 minutes.

Number of patient	Nature of effect	Number of patient response after 15 minutes	Percent age	Number of patient response after 30 minutes	Percent age.
173	Complete relief	156	90.17%	162	93.55%
	Partial relief	17	9.83%	11	6.45%

Above table shows:-

1. Incidence of complete relief after 15 and 30 minutes are 90.17% and 93.55% respectively.
2. Incidence of partial relief after 30 minutes lowest 6.45%.
3. Incidence of "No effect" after 15 and 30 minutes is not present in our series of study.

TABLE NO. 18

Blood pressure and pulse rate assessment before and 30 minutes after treatment with diclofenac sodium injection in patients having moderate pain (Mean \pm S.D.).

Number of patient	Vitals	Before injection	After injection
152	Systolic blood pressure	134.26 \pm 8.20	122.31 \pm 8.20
	Diastolic blood pressure	92.56 \pm 5.50	87.58 \pm 5.50
	Pulse rate/mt.	74.39 \pm 4.95	70.84 \pm 4.95
	P \neq 0.001	P \neq 0.001	P \neq 0.001

Above table shows:-

1. Incidence of significant fall in systolic/diastolic, as well as pulse rate was found after 30 minutes of diclofenac sodium injection.

TABLE NO. 19

Blood pressure and pulse rate assessment before and 30 minutes after treatment with diclofenac sodium injection in patients having severe pain (Mean \pm S.D.).

Number of patient	Vitals	Before injection	After injection
173	Systolic blood pressure	145.68 \pm 10.61	128.31 \pm 10.61
	Diastolic blood pressure	95.10 \pm 7.16	87 \pm 7.16
	Pulse rate/mt.	77.58 \pm 6.27	70.52 \pm 5.27
	P \neq 0.001	P \neq 0.001	P \neq 0.001

Above table shows:-

1. Incidence of significant fall in systolic /distolic as well as pulse rate was found after 30 minutes of diclofenac sodium injection.

TABLE NO. 20.

Relationship between vitals in different groups after 30 minutes of injection.

Vitals	Moderate pain		Severe pain		Difference
	Before	After	Before	After	
Systolic blood pressure	134.26 \pm 5.20	122.31 \pm 8.20	11.95 \pm 8.20	145.68 \pm 10.61	128.31 \pm 10.61
Diastolic blood pressure	92.56 \pm 5.50	87.58 \pm 5.50	4.98 \pm 5.50	95.10 \pm 7.16	87 \pm 7.16
Pulse rate	74.39 \pm 4.95	70.84 \pm 4.95	3.55 \pm 4.95	77.58 \pm 6.27	70.52 \pm 6.27
					7.06 \pm 6.87

Above table shows:-

1. Incidence of significant fall of systolic, diastolic blood pressure as well as pulse rate in both type of pain, but more in case of severe pain.

TABLE NO. 21

Summary of adverse reactions in 325 patient treated with
Diclofenac sodium (Diclofenac) injection.

Number of patient	Side effects	After injection (within 30 minutes)	Percentage
325	Nausea	7	2.15%
	Vomiting	9	2.76%
	Diarrhoea	-	-
	Drowsiness	13	4.03%
	Dry mouth	3	.93%
	Any other	-	-

Above table shows:-

1. Incidence of drowsiness is maximum 4.03%.
2. Incidence of dry mouth is minimum .93%.

D I S C U S S I O N

DISCUSSION

Acute renal/ureteric colic is fairly common problem in Bundelkhand region. Although urolithiasis is known for more than 7,000 years, little attention was directed to localization of stones or to the cause of its formation. It was only during last few years that attention has been paid to understand the cause of colic in stone diseases.

Though stones in kidney and bladder may remain asymptomatic, ureteric and kidney stones cause recurrent attacks of severe pain to the patients and may ultimately lead to damage of kidney due to stasis and infection.

Our present work is a clinicopathological study on three hundred twenty five (325) cases of acute renal/ureteric colic. An attempt has been made to evaluate the analgesic effects of intramuscular administration of Diclofenac sodium (Dicloren) injection on acute renal/ureteric colic.

Incidence : Approximately we had 26070 admissions (from April 1990 to April 1991) in this hospital and out of this 720 patients were of acute renal/ureteric colic (2.77%). However number of cases compiled for study were three hundred twenty five out of total seven hundred twenty (720) cases of ureteric colic. The rest

of the cases were excluded either because of incomptetion of the study or due to non coperation of the patients.

SEX : It is a well known fact acute renal/ureteric colic are more common in males than in females, ratio being 3:1 (George W.Drech; Black lock, 1969 (6)). This facts has also been established in our study of three hundred twenty five (325) patient. We have also the same ratio with male preponderance (243 males and 82 females). Perhaps female hormones affect the ureter in such a way as to prevent stones from lodging there.

Age : Acute renal/ureteric colic is more common in between 15-35 years of age. We did not find any case below 5 years of age or above 55 years of age. Burkland and Rosenberg, 1955 (62); Prince and Seardind, 1960(63) have reported the maximum incidence between 30-50 years of age.

Religion : Though we have observed that Hindus pre-dominate in our series (286-88%). This could be because of their dietary habits i.e. more consumption of milk and milk products, green leafy vegetables, tomatoes etc. or It may be general reflection of the population ratio.

Occupation : Hard work by manual labourers is associated with greater loss of water from body and leads to passage of highly concentrated urine, which may be responsible for its higher incidence in labourers. This fact has also been observed in our study (53.26%).

Socio-economic status : It is a well established fact that ureteric colic is commonest among the poorly nourished people. There is some evidence that it is a deficiency disease. However as patients of middle socio-economic class attend more for institutional therapy, more cases have been reported in our study (60.28%). Anderson², in 1972 (2) reported that ureteric colic are more common in persons of lower and upper middle socio-economic class.

Diet : It has been observed in this series that vegetarians predominate (62.12%) vegetarian diet may be containing some crystalloid substances, which precipitate in concentrated urine.

Alcohol : No definite role of alcohol has been established so far, but we feel that alcohol causes diuresis and may be helpful in spontaneous expulsion of small stones. Only 20.92% of the cases in our series were alcohol consumers.

Ingestion of excessive amount of food stuffs, which contain high amount of purines (meat, fish) oxalates (green leafy vegetables and tomatoes) and calcium (Milk and milk products) may lead to increase in excretion of these substances in urine, which in turn may lead to increase in incidence of urinary stones as well as ureteric colic.

Symptoms : There are three common symptoms in our series of study. Pain is the commonest symptom present in all cases (100%). It is well known that renal colic arises from the kidney associated with the inflammation or obstruction at the pelviureteric junction or in ureter. This ureteric obstruction causes increased synthesis and release of prostaglandins. As a result renal pelvic pressure rises, causing renal colic. (Lundström and Wahlander) (40).

Clinically haematuria is present in only seventy one patients (21.84%). Stones are of importance when they obstruct urinary flow or produced ulceration and bleeding. That bleeding originates from the lesions which cause erosions or disruption of blood vessels or from inflammatory changes which in turn lead to erosion and dispedisis of red cells.

Burning during micturition is present in one hundred and sixty one patients (49.56%). Infection

favours the formation of urinary calculi. Both clinical and experimental data suggest that formation is common when the urine is infected with urea splitting streptococcus, staphylococcus or proteus. The predominant bacteria found in the nuclei of urinary calculi are a staphylococcus and Esch. Coli. The stones also predispose to superimposed infection, both by their obstructive nature, and by the trauma they produce.

Microscopical examination of urine : It is well known that infection favours the formation of urinary calculi. In our series pus cells were present in seventy one (71) patients (21.85%). The stone is also liable to be cause of secondary infection both by their obstructive nature and by the trauma they produce.

Red blood cells present in one hundred and thirty two patients (40.92%). Stones cause the obstruction which further leads to ulceration and bleeding, that bleeding originates from the erosions or the inflammatory changes caused by stones due to trauma. (20). Out of the total three hundred twenty five patients, in 146 patients (45.26%) urine examination was reported to be normal.

Radiological features

1. Plain X-ray (KUB) : Plain X-ray KUB was done in all cases who were diagnosed clinically as having acute renal/urteric colic. We have observed that only in 40% cases

radio-opaque shadow suggestive of stone was found and 60% X-ray have no radio-opaque shadow. Probable explanation is either stones are too small in size, that they could not be visualized in plain X-ray or the patient's abdomen was not prepared properly before X-ray or the stone could be radiolucent.

2. Site of stones : We have observed that ureteric stones are most common in lower one third (24.62%) of ureter, ⁴⁹ Mikkleson et al (94) also reported in 1966 that stones are more common in lower half (62.5%) in their study of 24 patients.

3. Side of stones : Renal /ureteric stones should occur with same frequency on both sides, but we have observed that they are more common on right side, the cause of which could not be ascertained (72.31%).

4. I.V.P. : Out of three hundred and twenty five patients ninety two patients in whom I.V.P. was done. No abnormality was found in 10 cases (10.86%). The rest 89.14% cases had either non visualized /poorly visualized, Kidney on the side of pain or had shown hydronephrosis/hydroureter or both.

Severity of pain : Out of total number of three hundred and twenty five patients, hundred fifty two (152) that is about 46.76%, were having moderate pain where as one hundred and seventy three (173) of them that is about

53.2% were suffering from severe pain. No patient reported mild degree of pain in our study.

The experimental studies of Kill P (33) documented the physiological changes occurring during ureteric obstruction. Abe et al and Schramm and Carlson studied the release of prostaglandins during ureteric obstruction. These studies suggest the following sequence of events in ureteral obstruction.

1. Renal pelvic distention
2. Release of PGE_2 from renal medulla
3. Causes diuresis
4. Increase pelvic distention and pain

Use of prostaglandin inhibitors for relief of pain:

Prostaglandin inhibitors act possibly through following effects to relieve the pain in Renal/ureteric colic.

1. Block release of PGE_2
2. Reverse the diuretic effect
3. Reduce renal pelvic distention

Effect of diclofenac sodium (Inj. Dicloren) after 15 and 30 minutes of injection, on pain :

A. Moderate Pain group : The hundred and fifty two (152) patients of moderate pain group were given inj. diclofenac sodium intramuscularly deep in the gluteal region and the response to it was noted after 15 minutes and 30 minutes of the injection respectively. Complete relief was found in sixty two patients (40.79%) after

15 minutes. Where as partial relief was experienced by the rest ninty patients (59.21%). There was no patient who did not report relief. The number of patients experiencing complete relief at the end of 30 minutes rose to hundred and thirty one (131) where as partial relief was reported by remaining twenty one (21) patients. Not even a single patient reported absence of response after 15 minutes and 30 minutes of the injection.

B. Severe pain group : Complete relief in colic was reported by 156 (90.17%) patients out of 173 complaining of severe pain, after 15 minutes of the given injection, where as 17 (9.38%) reported partial relief in pain at the end of same time. After 30 minutes the number of patients reporting complete relief rose to hundred and sixty two (93.55%) where as only eleven were left with partial relief. No patient reported absence of effect of the drug.

The superlative number of the patients having complete relief after the first 15 minutes of the given injection in severe pain category of 156 in comparison to the moderate type ^{two} sixty was note worthy.

⁴⁰ Lundstam, Wahlander (40) and others in their study regarding "prostaglandin synthetase inhibitor with diclofenac sodium of treatment of acute renal/ureteric colic" have reported partial or complete relief of pain within 30 minutes of injection in 31 out of 34 patients they studied.

⁶⁷
R.Mirrales, J. Cami (64) and others (1987) in their study " Diclofenac versus dipyrene in acute renal colic" have reported that no difference were found between the groups in terms of satisfactory relief of pain ($7/15$ improvement in initial pain), which was achieved in 22 of 27 diclofenac treated patients (81.4%), and in 15 of 27 dipyrene treated patients (65.2%). In order to study the extent of improvement in pain intensity, pain rating 30 minutes after drug administration, reported that diclofenac was better than dipyrene in terms of improvement in pain intensity and the proportion of patients obtaining complete relief of pain at 30 minutes, but there was no difference between the drugs in terms of satisfactory relief of pain.

²⁶
In another study of Mr. Hetherington (25) "diclofenac sodium versus pethidine in acute renal colic" showed satisfactory relief of pain after a single shot within 30 minutes of injection in 28 (93%) out of 30 patients studied.

Our present study shows that intramuscular injection of a compound that inhibit prostaglandin synthesis is remarkably effective in treating attacks of renal/ureteric colic. Renal colic is caused by tension in the wall of renal pelvis due to rise in pressure above the ureteric obstruction. This elevation of pressure in renal pelvis stimulates prostaglandin synthesis, which increases diuresis, causing a further rise in pressure. The rationale for using prostaglandin synthetase inhibitors in the treatment of renal colic

is thus to counteract the increased synthesis and release of prostaglandins, which are of pathogenetic importance in this condition.

Blood Pressure and pulse rate

Noticeable decrease was found in both systolic and diastolic blood pressure and pulse rate after 30 minutes of injection in both moderate and severe pain category. The variation was more marked in the severe pain category in blood pressure and pulse rate as well.

The difference between the systolic blood pressure in moderate pain was on an average 11.95 mmHg with 8.20 as standard deviation whereas in severe pain category the difference was 17.37 mmHg with 10.61 as the standard deviation. The difference in diastolic blood pressure was 4.98 mmHg and 8.10 mmHg in moderate and severe pain category respectively with 5.50 and 7.16 as the standard deviation in the same sequence. The difference in pulse rate per minute was 3.55 and 7.06 with 4.95 and 6.87 as the standard deviation in the moderate and severe pain category respectively, the value of "p" being more than 0.001.

The fall of blood pressure and pulse rate is statistically significant. Though the fall was significant however it was of no clinical consequence.

A similar slight but statistically significant fall was noted by Lundstam, Wahlander (40) and other in their study " effect of diclofenac sodium in treatment of renal colic". Such a fall may be attributed to relaxation of accentuation of blood pressure following the relief of pain.

⁶⁷ R.Mirrales, J.Cami (64) and other in their study "diclofenac versus dipyrone in acute renal colic" have reported a significant decrease in mean blood pressure (Systolic and diastolic) and the cardiac rate after analgesic treatment with diclofenac sodium. The observed decrease in blood pressure and cardiac rate occurred at the same time as the relief of pain. This suggest that the first evaluation might have been influenced by the stress of the painful situation.

Side effects :

Out of the total three hundred and twenty five patients, drowsiness was reported by thirteen patients (4.03%) vomiting by nine patients (2.76%), nausea by seven patients (2.16%) and 3 patients (9%) complained of dry mouth.

The drugs commonly used for relief of acute renal/ureteric colic belong to the following groups.

- a. Narcotic analgesic e.g. pethidine, pentazocine etc.
- b. Non narcotic analgesic/antispasmodic combinations
e.g. Baralgan.

c. Prostaglandin inhibitor : e.g. indomethacin, diclofenac sodium.

a. Narcotic analgesics

1. Pethidine is a synthetic morphine substitute its common side effects are :

Vomiting, dry mouth, blurred vision, sedation, but over dose can cause CNS stimulation (Tremors, convulsions), respiratory depression and pethidine dependence occurs. Laurence Pharma text book.

2. Pentazocine (Fortwin) : is an opiate antagonist and its common side effects are - nausea, vomiting, dizziness, sweating, Hypertension, palpitations, tachycardia, CNS disturbances (Euphoria, dysphoria) withdrawl syndrome in addicts, it can also induce physical dependence. (Laurence Pharma text book).

b. Non narcotic analgesic/antispasmodic combination

1. Paralasen is a combination of dipyroone which is an analgesic, a benzaphenone component which is a smooth muscle relaxant and a diphenyl derivative which has a parasympatholytic action.

The common side effects are :-

dyspepsia, epigastric discomfort, nausea, vomiting, peptic ulcer, skin rashes, euphoria, blurring of vision allergic agranocytosis, blood dyscrasias, hypotension etc. (Laurence Pharma text book).

c. Prostaglandin inhibitor

1. Indomethacin : This is a indole acetic acid derivative and its common side effects are :- Nausea, vomiting, dyspepsia, peptic ulcer, Headache, giddiness, mental confusion, blurring of vision and depression etc.

Diclofenac sodium is a sodium salt of 2-(2,6-diclo-rophenylamino)-Phenylacetic acid, its side effects as reported by Willkens 1985 (63).

Gastrointestinal (10.2%) e.g. Nausea/vomiting and gastric upset etc.

CNS (.3%) e.g. dizziness, drowsiness and headache.

Allergic or local (.4%) e.g. rash etc.

others (1.6%) e.g. visual disturbance, oedema etc.

Lundstrom, Wahlander ⁴⁰ (40) and others in their study reported that the side effects were less common with diclofenac sodium than with spasmofen. Drowsiness and nausea were near about equally prevalent, condevably the long duration of pain, often with disturbed sleep, could explain the drowsiness and nausea/vomiting is common in attacks of renal/urteric colic. Thus these symptoms should not necessarily be considered side effects of treatment. It is likely, however, that larger doses of narcotic analgesic would significantly increase the side effects.

In our study we have observed that the intramuscular injection of prostaglandin synthetase inhibitor diclofenac sodium is fairly effective in relieving pain of acute renal/ureteric colic.

It is suggested that this treatment looks an attractive alternative that might replace narcotic drugs in the routine management of this common disorder, because of effectiveness and minimal side effects. However more clinical studies are required to make a final judgement about the drug.

CONCLUSIONS

CONCLUSION

The present " clinicopathological study of acute renal colic and evaluation of diclofenac sodium as an analgesic " was carried out over a period one year from April, 1990 to April, 1991. The study was conducted on (325) Three hundred and twenty five admitted patients of acute renal/ureteric colic in M.L.B. Medical College, Hospital, Jhansi during the above period. Injection diclofenac sodium (Dicloren) 75 mg intramuscularly was given and its effects over acute renal/ureteric colic pain was observed. Following conclusions have been drawn from this present study.

1. Approximately we had 26070 admissions in one year, in this hospitals and out of this 720 patients were of acute renal/ureteric colic (2.77%).
2. Symptomatic acute renal/ureteric colic are more common in males than females, rate ratio being 3:1.
3. Acute renal/ureteric colic is more common in between 15-35 years of age (81.08%), with peak incidence between 26-35 years (45.54%).
4. Acute renal/ureteric colic is more common in Hindu population (88%) as compared to patients of other religions.
5. Acute renal/ureteric colic is more common in highly manually active persons (53.25%) like farmers, labours etc.

6. Acute renal/ureteric colic is more common in middle socio-economic class of persons (60.28%).
7. Acute renal/ureteric colic is more common in predominantly vegetarian people (62.12%).
8. Acute renal/ureteric colic is more common in persons who do not consume alcohol (79.08%).
9. Pain, burning during micturition and haematuria are leading symptoms, 100%, 49.56% and 21.84% respectively.
10. Red blood cells, pus cells and epithelial cells are common microscopical examination findings in urine 40.92%, 21.85% and 19.22% respectively. However 45.26% had no findings in urine microscopic examination.
11. Radio-opaque shadow in plain KUB X-ray is present only in (40.49%) cases. In rest 60% cases do not show any radio-opaque shadow. It is an important finding.
12. Urteric stones are more common (57.70%) in comparison to kidney stones.
13. Urteric stones are more common in lower 1/3 of ureter (24.62%) followed by upper ureter (20.77%).
14. Renal/urteric stones are more common on right side (72.31%) than on left side (27.70%).
15. About 89.13% patients out of 92 patients in whom IVP was possible showed one or the other abnormality due to presence of stone.

16. One hundred and seventy three patients (53.24%) are suffering from severe pain followed by moderate pain (46.76%). None of the patient reported mild pain.

17. The potential effect of injection diclofenac sodium in words of complete relief were more worked in severe pain category (90.17%) in comparison to moderate pain category (40.79%) after 15 minutes of injection.

18. The number of patients experiencing complete relief at the end of 30 minutes rose to 86.22% and 93.55% in moderate and severe pain category respectively. There was no patient who did not report relief.

19. There is noticeable decrease in blood pressure (systolic & diastolic) and pulse rate in both category after 30 minutes of injection, but difference in systolic blood pressure in severe category is 17.37 mmHg in comparison to moderate type 11.95mmHg. However the fall in B.P. and pulse rate were not of clinical significance.

So from above study we can safely say that -

1. It is not essential to see a radio-opaque shadow in all the cases of acute renal/urteric colic.
2. It is not essential to see abnormality in the urine in all the cases, suffering from Acute renal/urteric colic.

3. Injection diclofenac sodium is a very effective alternative with minimal of side effects in the treatment of acute renal/urteric colic pain.

However further studies are required to make a final judgement on the above statements.

BIBLIOGRAPHY

BIBLIOGRAPHY

1. Arruda, J.A.L. : " Obstructive Uropathy".
Issues Nephrol (1983).
2. Anderson, D.A.: Environmental factors in the etiology of urolithiasis in urinary calculi, 1973.
3. Alward M. Maddock J. Jones F. Simultaneous pharmacokinetics of antirheumatic drugs in plasma and synovial fluids of rheumatoid patients. Abstract presented at the world Congress of Clinical Pharmacology and Therapeutics, London, 1980.
4. Brogden R.N. et al: Diclofenac sodium. A review of its pharmacological properties and therapeutic use in rheumatic disease and pain of varying origin. Drugs (1984).
5. Benson M.D., Aldo Benson M. Brandt K.D. Synovial fluid concentrations of diclofenac in patients with rheumatoid arthritis or osteoarthritis. Seminar in Arthritis and Rheumatism 15 (Suppl. 1): 65-67, 1985.
6. Bailey and Love's (1988) Surgery text book.
7. Blacklock, M.J.: The pattern of urolithiasis in Royal Navy. In Hodgkinson, A., and Nordin, B.K.C (Edi.): Renal stone research symposium, P 53. London, J & A Churchill Ltd., 1969.
8. Boyce, W.H. Garvey, and King N.E.: Incidence of urinary calculi among patient's in general hospital 1948-1952. JAMA 161, 1437, 1959.

9. Brendl K. Bruhn R. Ganote D.P., Ducker P.W.
Scholz H.J. Imadyl die gastrische Imtation in
Vergleich zu Acetylsalicylsaure, Indometacin,
Piroxicam and Diclofenac Na Methods and Findings
in Experimental and Clinical Pharmacology 5:579-580,
1983.
10. Bruhn R. Brendl K. Ganote D.P., Lucke P.W.,
Scholz H.J. Magenverträglichkeit nicht-steroidaler
Antirheumatika. Fortschritte der Medizin 100:1661-1667,
1982.
11. Coe F.L. and Parks J.H. : Pathogenesis of kidney
stones and strategies for treatment, Hosp. Pract.
23:185 (1988).
12. Consensus conference : Prevention and treatment of
the kidney stones, JAMA 260, 1980.
13. Chamouard J.M. Barre J. Unen S. Houin G. Tillement
J.P. Diclofenac binding to albumin and lipoproteins
in human serum. Biochemical pharmacology 34:1695-
1700, 1985.
14. Dorietto de Menezes M.R. Catanzaro-Guimaraes S.A.
Determination of anti-inflammatory and antimitotic
activities of non steroid anti-inflammatory drugs
ibuprofen, diclofenac sodium and fentazac. Cellular
and Molecular Biology 31: 455-461, 1985.

15. Edmond C.K.U., Jong M.: Diclofenac sodium a potent inhibitor of prostaglandin synthetase. *Biochem Pharmacology* (1975).
16. Elliott, J.P. Jr.: A stone season a ten year retrospective study of 768 surgical stone cases with respect to seasonal variation. *J. Urol.* 114: 574, 1975.
17. Finlayson B.: Symposium on renal lithiasis Renal lithiasis in review, *Urol. Clin. N. Am.* 1:181, 1984.
18. Friman C. Johnston C. Chew C. Davis P. Effect of diclofenac sodium, telefenamic acid and indomethacin on the production of superoxide induced by N-formyl-methionyl-leucyl-phenylalanine in normal human polymorphonuclear leukocytes. *Scandinavian Journal of Rheumatology* 15: 41-46, 1986.
19. Gutman, A.B. and Yu T.P. uric acid neoprolithiasis. *Am. J. Med.* 45:756, 1968.
20. Geiger UF, Degen PH, Sioufi A. Quantitative assay of diclofenac in biological material by gas-liquid chromatography. *Journal of Chromatography* 111:293-298, 1975.
21. Gross W. Kreh J. Krebs A. Zoller H. diclofenac sodium blood concentration of the slow-release form and influence on the metabolism of kallikrein. *Arzneimittel -Forschung* 34:1327-1329, 1984.

22. Grossi E. Broggini M. Quaranta M. Balestrino E. Different pharmacological approaches to the treatment of acute biliary colic. Current Therapeutic Research 40:876-882, 1986.

23. Huskisson, E.C., Hant, F.D. 1974, 70

24. Newer, A.J.H. Keele K.D. etc. Lancet 1949; 431.

25. Holmiund D. Sjodin G. Indomethacin in treatment of ureteric colic. Surg. Forum 1978:29:639-41.

26. Hetherington J.W., Diclofenac sodium versus pethidine in acute renal colic. B.M.J. Vol. 292: 25 Jan. 1986, 237-8.

27. John F. Gagnon PT. Inhibition of human platelet aggregation by a dibenzazepine compound (GP 44296) and by N- (2,6-dichlorophenyl) - o-aminophenylacetic acid (GP45840). Canadian Journal of Physiology and Pharmacology 49:479-481, 1971.

28. John VA. The pharmacokinetics and metabolism of diclofenac sodium (Voltarol) in animals and man. Rheumatology and Rehabilitation (Suppl 2, 22-35, 1979.

29. K. Das 1990 Clinical surgery -Text book of Surgery.

30. Kantor TG. Use of diclofenac in analgesia. American Journal of Medicine 80 (Suppl. 48) 64-69, 1986.

31. Kendall MJ, Thornhill DP, Willis JV. Factors affecting the pharmacokinetics of diclofenac sodium. *Rheumatology and Rehabilitation* (Suppl. 2): 38-45, 1979.
32. Klahr, S. et al: *Urinary tract obstruction.* W.B. Saunders Co. (1986).
33. Kill F.: *The function of the ureter and renal pelvis* :W.B.Saunders Company Philadelphia (1987).
34. Keele, K.D. *Lancet*, 1948; ii:6.
35. Keele, K.D. *B.M.J.*, 1968; i:670.
36. Karpukhin, V.T. et al: *Conservative treatment of ureteral calculi* vestin khir 1981 July 127(7): 117-20.
37. Kral JC. *Analgesic effects of prostaglandin synthesis inhibitions by diclofenac sodium.* *Seminars in Arthritis and Rheumatism* 15(Suppl. 1):93-96, 1985.
38. Krupp P, Menasse R, Riesterer I, Ziel R. *The biological significance of inhibition of prostaglandin synthesis in Lewis (Ed).* The role of prostaglandins in inflammation, pp. 108-121, Hans Huber Publishers Bern. 1976.
39. Ku EC, Lee W, Kothari HV, Kimbic EF, Liauw I. et al. *The effects of diclofenac sodium on arachidonic acid metabolism.* *Seminars in Arthritis and Rheumatism* 15 (Suppl. 1): 36-41, 1985.

40. Lundstam S., Wahlander L.: Prostaglandin synthetase inhibition with diclofenac in treatment of renal colic comparison with use of a narcotic analgesia. *Lancet* 1: 1096-1097.

41. Lonsdale K. Epitaxy as a growth factor in urinary calculi & gall stones. *Nature*, 217:56; 1968.

42. Laurent J. Belghiti D. Bruneau C. Lagrue G. Diclofenac, a non steroid anti-inflammatory drug decreases proteinuria in some glomerular diseases. a controlled study. *American Journal of Nephrology* 7: 198-202, 1987.

43. Lehtola J. Sipponen P. A gastrescopic and histological double blind study of the effects of diclofenac sodium and naproses on the human gastric mucosa. *Scandinavian Journal of Rheumatology* 6:97-102, 1977.

44. Liauw H. Walter S. Lee L. Ku E. Effects of diclofenac on synovaleicosanoid product formation in arthritis patients. *Abstract Journal of clinical Pharmacology* 25:456, 1985.

45. Mindstam S. Leissner K.H. Wahlander L.A. Kral J.G. Prostaglandin-synthetase inhibition with diclofenac sodium in the treatment of renal colic comparison with use of a narcotic analgesic. *Lancet* 1:1096-1097, 1982.

46. Mindstam S. Wahlander L. Kral JG. Treatment of ureteric colic by prostaglandin synthetase inhibition with diclofenac sodium. Current Therapeutic Research 28: 355-358, 1980.

47. Mindstam S. Wahlander L. Kral JG. Prostaglandins synthesis inhibition by diclofenac sodium in biliary pain. Abstract European Journal of Clinical Investigation 13: A1, 1983.

48. Maier R. Menasse R. Riesterer L. Pericin C. Ruegg M. et al. The pharmacology of diclofenac sodium (voltarol) Rheumatology and Rehabilitation (Suppl.2): 11-21, 1979.

49. Mikkelsen, A.H. et al.: The effect of hydroxypyrostosterone on ureteral stones. Int. Urol. Nephro. 1988: 20(3): 257-60.

50. Miralles, R. Came. J.: Diclofenac versus dipyrone in acute renal colic " 4 double blind controlled trial Eur. J. Clin. Pharmacol. (1987).

51. Marsala F.: Treatment of ureteral and biliary pain with an injectable salt of indomethacin. Pharmacotherapeutics, 1980, 2: 357-362.

52. Menasse R. Et al.: Pharmacological properties of diclofenac sodium & its metabolites. Scand J. Rheum. (1978).

53. Martini A. Bondioliotti GP. Sacerdote P. Pierro L. Picotto GB. et al. Diclofenac increases beta-

endorphin plasma concentrations. *Journal of International Medical Research* 12: 92-95, 1984.

55. Menasse R. Hedwall PR. KRACTZ J. Pasicin C.

Riesterer L. et al. Pharmacological properties of diclofenac sodium and its metabolites Scandinavian Journal of Rheumatology (Suppl. 22): 5-16, 1978.

55. Modlin M.: The aetiology of renal stone: A new concept arising from studies on stone free population. *Ann. R. Coll. Surg. Engl.* 40: 155, 1967.

56. Naveh D. Treatment of renal colic with intramuscular injection of diclofenac sodium. *Harefush* 102: 375-376, 1982.

57. Nogidichoi Y, Ishiko J, Ohtsuki I. Comparative pharmacological profiles of piroxicam, indomethacin, phenylbutazone, diclofenac, ibuprofen and mefenamic acid. *Royal Society of Medicine International Congress and Symposium Series* 67:61-67, 1984.

58. Oliw E, Lunden I, Anggard E. In vivo inhibition of prostaglandin synthesis in rabbit kidney by non-steroidal anti-inflammatory drugs. *Acta Pharmacologica* 42: 179-184, 1978.

59. Oanes M, Lensen S, Eidssunet W, Thom E. Effect of diclofenac and naproxen on gastroduodenal mucosa. *Clinical Pharmacology and Therapeutics* 26:399-405, 1979.

60. Pantonawitz, D. Pellen. I.J. Polatzev, W.M. et al.
Ureteric calculi: S. Afr. Med. J. 47, 128, 1973.

61. Prince C.L., Scardino, P.L. and Wolam, T.C.: The
effect of temperature humidity and dehydration on
the formation of renal calculi. J. Urol. 75:209,
1956.

62. Prince C.L. and Scardino, P.L.: A statistical analysis
of ureteral calculi. J. Urol. 83: 361, 1960.

63. Peter A. Todd and Eugene M. Sorkint Diclofenac
sodium - A reappraisal of its pharmacodynamic and
pharmacokinetic properties and therapeutic efficacy.
ADIS drug information services, Auckland Drugs 35-
244-285 (1988).

64. Quilez C. Perez-Maleo M. Hernandez P. Rubio I.
Utilidad de un antiinflamatorio no esteroideo
diclofenac sodico, en el tratamiento del colico
nefriaco; estudio comparativo con un espasmolitico
y un analgesico opioideo. Medicina Clinica 82:754-755,
1984.

65. Rosenberg, M. and Burkland, C.E.: Survey of uro-
lithiasis in united states. J. Urol. 73:198, 1965.

66. R.S. Shah etc. I.J.S. 1986; 350-354. Lancet Vol. II,
1974.

67. R. Miralles, J. Cami and Others. Diclofenac versus
dipyrone in acute renal colic. Eur. J. Clin. Pharmacol.
(1987) 33: 527-528.

68. Reimann IW, Frolich JC. Effects of diclofenac on lithium kinetics. Clinical Pharmacology and Therapeutics 30: 348-352, 1981.

69. Riess W, Stierlin H, Degen P, Faigle JW, Gerardin A, et al. Pharmacokinetics and metabolism of the anti-inflammatory agent voltaren. Scandinavian Journal of Rheumatology (Suppl. 22): 17-29, 1978.

70. Sacerdote P, Monza G, Mantegazza P. Diclofenac and pirprofen modify pituitary and hypothalamic beta-endorphin concentration. Pharmacological research communications 17: 679-684, 1985.

71. Sallmann AR. The history of diclofenac. American Journal Medicine 80 (Suppl. 48) 129-33, 1986.

72. Sami Khalifa M, Sharkwi MA. Treatment of pain owing to acute ureteral obstruction with prostaglandin synthetase inhibitor a prospective randomized study. Journal of urology 136: 393-395, 1986.

73. Schlumpf U. Der Einfluss von Diclofenac-Natrium auf den Stoffwechsel von Diabetikern unter qualitativer Diät mit und ohne Tolbutamid. Schweizerische Medizinische Wochenschrift 108:28-34, 1978.

74. Seppala E, Niissila M, Isomaki H, Nuotic F, Nykanen E, et al. Comparison of the effects of different anti-inflammatory drugs on synovial fluid prosta-

81.Uthgenann H. Letzel H. Gastrointestinal blood loss in volunteers following fenclofenac and idiclofenac, British Journal of Clinical Practice 35: 229-232, 1981.

82.Vignoni A, Pierro A, Moreschini G, Can M. Agostinelli A. : Diclofenac sodium in ureteric colic. Double blind comparison trial with placebo J. Int. Med. Res. 11, 1983.

83.Vandenbroughe MJ. Currie WJC. Mann SG. Diggins JB. Differential effects of two nonsteroidal anti-inflammatory drugs on the plasma urea of elderly patients with osteoarthritis. British Journal of Clinical Practice. 38: 403-406, 1984.

84.Woller and Greene : Reference book examination of urine. 3-6.

85.Wagner J. Sule M. Binding of diclofenac sodium (Voltaren) to serum proteins of different species and interactions with other drugs in protein binding. Aktuelle Rheumatologie 4:153, 1979.

86.Willis JV, Kendall MJ. Flinn RM. Thornhill DP. Welling PG. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. European Journal of Clinical Pharmacology 16:405-410, 1979.